This study is testing a drug called axelopran in people with advanced breast, lung (non-small cell lung carcinoma), pancreas, or prostate cancer that has progressed after standard treatments. The main goal is to see if axelopran can help control cancer growth. Researchers will also look at whether axelopran is safe for long-term use, improves bowel function and quality of life, and reduces inflammation. The study plans to enroll 34 adults (18 years or older) who have these specific types of cancer. Success in this study will be measured by how many participants experience a complete or partial response to the treatment, which will be assessed after 43 days.

Study design

This is a single-arm, open-label study, meaning all participants will receive axelopran and both you and the study team will know which treatment you are getting. It plans to enroll 34 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary study period for assessing the main goal is through day 43 (6 weeks).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.